Blood stem cell transplantation for breast cancer: new approaches using pre- peri- post-transplant immunotherapy

Bibliography

• GALE RP, PARK RE, DUBOIS R et al.: Delphi - panel analyis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. OM Transplant. (2000) 14:32–41.
   Web of Science ®Google Scholar
• •Nine experts rated 2058 clinical settings for appropriateness of auto-PBSCT.
   Google Scholar
• ROWLINGS PA,WILLIAMS ANTMAN KH et al.: Factors correlated with progression free survival after high dose chemotherapy and hematopietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 282:1335–1343.
   Google Scholar
• •Retrospective analysis of 1188 women on independent risk factors for relapse.
   Google Scholar
• NIETO Y, CHAMPLIN RE, WINGARD JR et al.: Status of high - dose chemotherapy for breast cancer: a review. Biol. Blood Marrow Transplant. (2000) 6:476–495.
   PubMed Web of Science ®Google Scholar
• •Analysis of Phase II/III trials of auto-PBSCT compared to conventional chemotherapy.
   Google Scholar
• STADTMAUER EA, O'NEILL A, GOLDSTEIN LJ et al.: Conventional dose chemotherapy compared with high dose chemotherapy plus autologous hematopoietic stem cell transplantation for metastatic breast cancer. N Engl. J. Med. (2000) 342:1069–1076.
   Google Scholar
• BRODOWICZ T, AUERBACH L, ZIELINSKI C: High dose chemotherapy plus hematopoietic stem cell rescue for metastatic breast cancer. N Engl. j. Med. (2000)343:439–440.
   Google Scholar
• LOTZ JP, CURE H, JANVIER M et al.: Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04. Hematol Cell Ther. (1999) 41:71–74.
   PubMedGoogle Scholar
• CRUMP M, GLUCK S, DOUGLAS S et al: A randomized trial of high - dose chemotherapy with autologous peripheral blood stem cell support compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group Study. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 82.
   Google Scholar
• RODENHUIS S, BONTENBAL M, BEEX LVAM et al: Randomized phase III study of high dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 286.
   Google Scholar
• GIANNI A, BONADONNA G: Five year results of the randomized clinical trial comparing standard versus high dose myeloablative chemotherapy in the adjuvant treatment of breast cacner with 3 positive nodes (LN+). 37th Annual Meeting of the American Sot:leo, of Oncology (ASCO) (2001). Abstract 80.
   Google Scholar
• HORTOBAGY GN, BUZDAR AU, THERIAULT RL et al.: Randomized trial of high dose chemotherapy and blood cell autografts for high risk primary breast carcinoma. j. Natl. Cancer Inst. (2000) 92:225–233.
   PubMed Web of Science ®Google Scholar
• ROCHE HH, POUILLART P, MEYER N et al.: Adjuvant high dose chemotherapy improves early outcome for high risk (N>7) breast cancer patients: the Pegase 01 Trial. 37 th Annual Meeting of the American Sot:leo, of Oncology (ASCO) (2001). Abstract 102.
   Google Scholar
• PETERS W, ROSNER G, VREDENBURGH J et al.: Updated results of a prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high risk primary breast cancer involving ten or more axillary lymph nodes: CALGB 9082/ SW0G9114/NCIC Ma-13. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 81.
   Google Scholar
• KUREBAYASHI JJ: Biological and clinical significance of her2 overexpression in breast cancer. Breast Cancer (2001) 8:45–51.
   PubMedGoogle Scholar
• BRAUN S, PANTEL K, MULLER P et al.: Cytokeratin - positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl. j. Med. (2000) 342:525–533.
   PubMed Web of Science ®Google Scholar
• •Minimal residual disease is an independent risk factor for poorer outcome.
   Google Scholar
• BALLESTER OE FANG T, WILCOX P et al.: New high dose therapy regimens for metastatic breast cancer. Can they improve outcomes? 37th Annual meeting of the American Sot:leo, of Onclogy (ASCO) (2001). Abstract 1752.
   Google Scholar
• HU WW, NEGRIN RS, STOCKERL - GOLDSTEIN et al: Four-cycle high dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high - dose therapy. Biol. Blood Marrow Transplant. (2000) 6:58–69.
   PubMed Web of Science ®Google Scholar
• ELIAS AD, RICHARDSON P, AVIGAN D et al.: A short course of induction chemotherapy followed by two cycles of high dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant. (2001) 27:269–278.
   PubMed Web of Science ®Google Scholar
• FEFER A: Graft versus tumor response. In: Hematopoetic Cell Transplantation. ED Thomas, KG Blume, SJ Forman (Eds.), Blackwell Science, Boston (1999):316–326.
   Google Scholar
• ••Elaborates pathophysiology and clinicalresults of GVT.
   Google Scholar
• UENO NT, RONDON G, MIRZA NQ et al.: Allogeneic peripheral blood progenitor cell transplantation for poor risk patients with metastatic breast cancer. j. Clin. Oncol (1998) 16:986–993.
   PubMed Web of Science ®Google Scholar
• •GVT effect associated with GVHD in ten metastatic breast cancer patients after allo-SCT.
   Google Scholar
• CARELLA AM, CHAMPLIN R, SLAVIN S, MC SWEENEY P, STORB R. Mini allografts: ongoing trials in humans. Bone Marrow Transplant. (2000) 25:345–350.
   PubMed Web of Science ®Google Scholar
• •Review on latest developments of non-myeloablative allo-SCT.
   Google Scholar
• LUZNIK L, ENGSTROM LW, FUCHS EJ, COUZI RJ: Significant antitumor activity of non-myeloablative allogeneic bone marrow transplantation and donor lymphocyte infusion in the treatment of metastatic breast cancer. 36th Annual Meeting of the American Socieo, of Oncology (ASCO) (2000). Abstract 389.
   Google Scholar
• BREGNI M, DODERO A, PECCATORI J et al: Graft versus tumor effect in advanced solid tumors following reduced intensity stem cell allografting. 37th Annual meeting of the American Society of Oncolocy (ASCO) (2001). Abstract 45.
   Google Scholar
• PORTER DL, CONNORS JM, VAN DEERLIN et al: Graft versus tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. j. Clin. Oncol (1999) 17:1234.
   PubMed Web of Science ®Google Scholar
• HESS AD, THOBURN CJ, CHEN W, HORWITZ LR: Complexity of effector mechanisms in cyclosporine-induced syngeneic graft versus host disease. Biol Blood Marrow Transplant. (2000) 6:13–24.
   PubMed Web of Science ®Google Scholar
• •Immunologic and molecularbiological explanation of auto-GVH induction
   Google Scholar
• VAN DER WALL E, HORN T, BRIGHT E et al.: Autologous graft versus host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br j. Cancer (2000) 83:1405–1411.
   Google Scholar
• NEGRIN RS: Prevention and therapy of relapse after autologous haematopoietic cell transplantation. In: Hematopoetic Cell Transplantation. Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science, Boston (1999):1123–1134.
   Google Scholar
• ••Thoroughly reviewed cytokine and cellmediated approaches.
   Google Scholar
• GUILLAUME TH, RUBINSTEIN DB, SYMANN M: Immune reconstitution and Immunotherapy after autologous hematopoietic stem cell transplantation. Blood (1998) 92:1471–1490.
   PubMed Web of Science ®Google Scholar
• ••Review connecting post-transplant deficitswith therapeutic approaches.
   Google Scholar
• PORRATA LE LITZOW MR, MARKOVIC SN: Immune reconstitution after autologous hematopoietic stem cell transplantation. Mayo Clin Proc. (2001) 76:407–412.
   PubMed Web of Science ®Google Scholar
• SHENOY S, MOHANAKUMAR T, TODD G et al: Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. (1999) 23:335–346.
   PubMed Web of Science ®Google Scholar
• STOREK J, DAWSON MA, STORER B etal.: Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 97:3380–3389.
   Google Scholar
• •Comprehensive synopsis of different stem cell sources.
   Google Scholar
• MARGOLIN K, FORMAN SJ: Immunotherapy with Interleukin - 2 after haematopoietic cell transplantation for haematologic malignancies. Cancer j. Li. Am. (2000) 6\(Suppl. 1):33–38.
   Google Scholar
• TOH HC, MCAFEE SL, SACKSTEIN R et al: A Phase II Study of high dose Cyclophosphamide + Carboplatin and Interleukin - 2 activated autologous peripheral blood stem cell transplantation followed by subcutaneous IL-2 therapy in metastatic breast carcinoma. Bone Marrow Transplant (2000) 25:19–24.
   PubMed Web of Science ®Google Scholar
• MEEHAN KR, ARUN B, GEHAN EA et al.: Immunotherapy with Interleukin 2 and alpha - Interferon after IL-2 activated hematopoietic stem cell transplantation for breast cancer. Bone Marrow Transplant. (1999) 23:667–673.
   PubMed Web of Science ®Google Scholar
• MITTAL P, CORTEGUERA B, ZHANG Y, GEHAN E, MEEHAN KR: Post transplant immunotherapy may improve long term survival in breast cancer patients. 37 th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 52.
   Google Scholar
• ••Follow up of [33]: improved PFS after IL-2activated stem cells plus post auto-PBSCT IL-2, IFN-a.
   Google Scholar
• HOLMBERG LA, OPARIN DV, GOOLEY T et al.: Clinical outcome of breast and ovarian cancer patients with high doe chemotherapy, autologous stem cell rescue and THERATOPE® STn-KLH cancer vaccine. Bone Marrow Transplant. (2000) 25:1233–1241.
   PubMed Web of Science ®Google Scholar
• •First report on vaccination after auto-PBSCT in breast cancer.
   Google Scholar
• REECE DE, FOON KA, BHATTACHARYA-CHATTERJEE M et al.: Use of the anti-idiotype antibody vaccine Triab after autologous stem cell transplantation in patients with metastatic breast cancer. Bone Marrow Transpl. (2000) 26:729–735.
   PubMed Web of Science ®Google Scholar
• REECE DE, FOON K, CHATTERJE Met al.: Vaccination with triab in conjunction with intensive therapy and autologous stem cell transplantation for patients with metastatic breast cancer. 36th Annual Meeting of the American Socieo, of Oncology (ASCO) (2000). Abstract 388.
   Google Scholar
• •Follow up of [34 vaccination starting prior auto-PBSCT is superior.
   Google Scholar
• BASHEY A, CORRINGHAM S, LAW P et al.: A Phase II Study of active specific immunotherapy with recombinant Mucin Peptide (MUC-1) after high dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 190.
   Google Scholar
• HEMPEL D, MULLER P, ORUZIO D etal.: Treatment of breast cancer with high dose chemotherapy followed by consolidation with monoclonal antibody 17/1A. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 481.
   Google Scholar
• REID DC: Dendritic cells and immunotherapy for malignant disease. Br. Haematol (2001) 112:874–887.
   PubMed Web of Science ®Google Scholar
• ••Review on tumour biology and DCs.
   Google Scholar
• SHURIN MR, LU L, KALINSKI P, STEWART- AKERS AM, LOTZE MT: Thl/Th2 balance in cancer, transplantation and pregnancy. Springer Semin. Immurropathol (1999) 21:339–359.
   PubMed Web of Science ®Google Scholar
• AVIGAN D, WU Z, JOYCE R et al.: Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. (2000) 26:169–176.
   PubMed Web of Science ®Google Scholar
• ROULEAU M, SENIK A, LEROY E, VERNANT JP: Long term persistence of transferred PPD-reactive T-cells after allogeneic bone marrow transplantation. Transplantation (1993) 55:72–76.
   PubMed Web of Science ®Google Scholar
• BORRELLO I, SOTOMAYOR EM, RATTIS FM, COOKE SK, GU L, LEVITSKY HI: Sustaining the graft versus tumor effect through posttransplant immunization with granulocyte-macrophage-colony-stimulating factor (GM-CSF) producing tumor vaccines. Blood (2000) 95:3011–3019.
   PubMed Web of Science ®Google Scholar
• ••Animal model of vaccination post auto-PBSCT in malignancy.
   Google Scholar
• TALMADGE JE, REED E, INO K et al.: Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant (1997) 19:161–172.
   PubMed Web of Science ®Google Scholar
• GALY A, RUDRARAJU S, BAYNES R, KLEIN J: Recovery of lymphocyte and dendritic cells subsets after autologous CD34+cell transplantation. Bone Marrow Transplant (2000) 25:1249–1255.
   PubMed Web of Science ®Google Scholar
• WELTE K, CIOBANU N, MOORE MA, GULATI S, O'REILLY RJ, MERTELSMANN R: Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin-2. Blood (1984) 64:380–385.
   PubMed Web of Science ®Google Scholar
• AGEITOS AG, SINGH RK, INO K et al.: IL-2 expansion of T and NK cells from growth factor - mobilized peripheral blood stem cell products:monocyte inhibition. Immunother. (1998) 21:409–417.
   PubMed Web of Science ®Google Scholar
• TALMADGE JE, SINGH R, INO K, AGEITOS A, BUYUKBERBER S: Mechanisms of immune dysfunction in stem cell transplantation. Int. Immurropharmacol (2000) 22:1041–1056.
   PubMed Web of Science ®Google Scholar
• ••Highly activated CD14+ monocytes causeCD4+ loss post auto-PBSCT.
   Google Scholar
• SINGH RK, INO K, VARNEY ML, HEIMANN DG, TALMADGE JE: Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. Bone Marrow Transpl. (1999) 23:53–62.
   PubMed Web of Science ®Google Scholar
• ARPINATI M, GREEN CL, HEIMFELD S, HEUSER JE, ANASETTI C: Granulocyte - colony stimulating factor mobilizes T helper 2 inducing dendritic cells. Blood (2000) 95:2482–2483.
   PubMedGoogle Scholar
• TANAKA J, MIELCAREK M, TOROK-STORB B: Impaired induction of the CD 28-responsive complex in granulocyte - stimulating factor mobilized CD4 Tcells. Blood(1998) 91:347–352.
   PubMed Web of Science ®Google Scholar
• MIELCAREK M, GRAF L, JOHNSON G, TOROK-STORB B: Production of Interleukin -10 by granulocyte colony stimulating factor mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood (1998) 92:215–222.
   PubMed Web of Science ®Google Scholar
• MEEHAN KR WUA, HASSAN R et al.: Er vivo activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy. j Hematother. Stem Cell Res. (2001) 10:283–290.
   PubMedGoogle Scholar
• WALDMANN TA, DUBOIS S, TAGAYA Y: Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity (2001) 14:105–110.
   PubMed Web of Science ®Google Scholar
• ••Role of IL-2 in AICD limiting its efficacypost auto-PBSCT.
   Google Scholar
• HINTERBERGER-FISCHER M, OGRIS E, KIER P et al.: Elevation of plasma prolactin in patients undergoing autologous blood stem cell transplantation for breast cancer: is its modulation a step towards posttransplant immunotherapy? Am. Chi]. arca (2000) 23:325–329.
   Google Scholar
• FERRARA JLM, ANTIN JH: The Pathophysiology of graft versus host disease. In: Haematopoetic cell transplantation. Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science, Boston (1999):305–315.
   Google Scholar
• •Comprehensive review on latest knowledge.
   Google Scholar
• DREGER P, SCHMITZ N: Allogeneic transplantation of blood stem cells: coming of age? Ann. Hematol (2001) 80:127–136.
   Web of Science ®Google Scholar
• POWELS R, MEHTA J, KULKARNI S et al.: Allogeneic blood and bone marrow stem cell transplantation in haematological malignant diseases: a randomized trial. Lancet (2000) 355:1231–1237.
   PubMed Web of Science ®Google Scholar
• BENSINGER WI, STORB R: Allogeneic peripheral blood stem cell transplantation. Rev Chi]. Exp. Hematol (2001) 5:67–86.
   PubMedGoogle Scholar
• •Analysis of randomised studies PBSC - BMT in clinical outcome (GVHD, OS, DFS).
   Google Scholar
• PAN L, DELMONTE J Jr., JALONEN Expert Op/n. Biol. Ther. (2001) 1(6)
   Google Scholar
• CK, FERRARA JL: Pretreatment of donor mice with granulocyte colony stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft versus host disease. Blood (1995) 86:4422–4429.
   PubMed Web of Science ®Google Scholar
• MILLER JS, PROSPER F, MC CULLAR V: Natural killer cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony stimulating factor mobilized blood progenitor cell collections. Blood (1997) 90:3098–3105.
   PubMed Web of Science ®Google Scholar
• REDDY V, HILL GR, PAN L etal.: G-CSFmodulates cytokine profile of dendritic cells and decreases acute graft versus host disease through effects on the donor rather than the recipient. Transplantation (2000) 69:691–693.
   Google Scholar
• PORRATA LE INGLE JN, LITZOW MR, GEYER SM, MARKOVIC SN: Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. 37th Annual Meeting of the American Sac:leo, of Oncology (ASCO) (2001). Abstract 33.
   Google Scholar
• GASTL G, MARTH C, LEITER E et al.: Effects of human recombinant alpha 2arg-interferon and gamma interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res. (1985) 45:2957–2961.
   PubMed Web of Science ®Google Scholar
• O'GARRA A: Cytokines induce the development of functionally heterogenous T helper cell subsets. Immunity (1998) 8:275–283.
   Google Scholar
• YOUNG JM: Immunotherapeutic applications of dendritic cells. Hematology 2000. American Society of Hematology Education Program Book. San Francisco (2000):361–366.
   Google Scholar
• ••Latest developments in DC search.
   Google Scholar
• DINARELLO CA: Interleukin-18. Methods (1999) 19:121–132.
   PubMed Web of Science ®Google Scholar
• MATERA L, MORI M, GEUNA M, BUTTIGLIERI S, PALESTRO G: Prolactin in autoimmunity and antitumor defence. j Neuroimmurrol (2000) 109:47–55.
   PubMed Web of Science ®Google Scholar
• •Review about a new cytokine and its antitumour properties.
   Google Scholar
• BURNS LJ, WEISDORF DJ, DEFOR TE et al: Enhancement of anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin-2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer. Exp. Hematol (2000) 28:96–103.
   PubMed Web of Science ®Google Scholar
• •First report on stem cell mobilisation with GM-CSF and IL-2.
   Google Scholar
• SOSMAN JA, STIFF P, MOSS SM etal.:Pilot trial of Interleukin-2 with granulocyte colony -stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high dose chemotherapy: expansion of immune effectors within the stem cell graft and post stem cell infusion. j CBI]. arca (2001)19:634–644.
   Google Scholar
• MEEHAN KR, VERMA UN, CAHILL R et al.: Interleukin 2 activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates. Bone Marrow Transplant. (1997) 20:643–651.
   PubMed Web of Science ®Google Scholar
• MILLER JS, TESSMER-TUCK, PIERSON BA et al.: Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol. Blood Marrow Transplant. (1997) 3:34–44.
   PubMedGoogle Scholar
• LOPEZ-JIMINEZ J, PEREZ-OTEYZA J, MUNOZ A et al.: Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non randomized study. Bone Marrow Transplant. (1997) 19:429–434.
   PubMed Web of Science ®Google Scholar
• GRAVIS G,VIENS P, VEY N etal.: Pilot study of immunotherapy with interleukin 2 after autologous stem cell transplantation in advanced breast cancer. Anticancer Res. (2000) 20:3987–3991.
   Google Scholar
• VIVANCOS P, GRANENA A Jr., SARRA J, GRANENA A: Treatment with interleukin -2 and Interferon - alpha 2b after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse. Bone Marrow Transplant. (1999) 23:169–172.
   Google Scholar
• BACHIER CR, LANZKRON M, HOUGHAM M et al: Interleukin - 2 and granulocyte macrophage colony stimulating factor for immune activation following autologous stem cell transplant increase lymphocyte subsets more than either drug alone. 36th Annual Meeting of the American Socieo, of Oncology (ASCO) (2000). Abstract 233.
   Google Scholar
• LI XC, DEMICRI G,FERRARI-LACRAZ etal.: IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat. Med. (2001) 7:114–118.
   Google Scholar
• KRUMENACKER JS, BUCKLEY DF LEFF MA et al: Prolactin regulated apoptosis of Nb2 lymphoma cells: pim-1, Bc1-2 and bax expression. Endocrine (1998) 9:163–170.
   PubMed Web of Science ®Google Scholar
• MATERA L, CONTARINI M, BELLONE G, FORNO B, BIGLINO A: Up-modulation of interferon-y mediates the enhancement of spontaneous cytotoxicity in prolactin activated natural killer cells. Immunology (1999) 98:386–392.
   PubMed Web of Science ®Google Scholar
• NAGLER A, ACKERSTEIN A, ORE, NAPARSTEK E,SLAVIN S: Immunotherapy with recombinant human interleukin 2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood (1997) 89:3951–3959.
   PubMed Web of Science ®Google Scholar
• VEY N, VIENS P, FOSSAT C et al.: Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin 2 after autologous bone marrow transplantation. Euro. Cytokine Network (1997) 8:389–394.
   PubMed Web of Science ®Google Scholar
• HEHLMANN R, HOCHHAUS A, BERGER U, REITER A: Current trends in the management of chronic myelogenous leukemia. Ann. Hematol (2000) 79:345–354.
   PubMed Web of Science ®Google Scholar
• BYKOVSKAIA SN, BUFFO M, ZHANG H et al.: The generation of human dendritic and NK cells from hemopoetic progenitors induced by interleukin 15.1 Leukoc. Biol. (1999) 66:659–666.
   Google Scholar
• COOPER MA, FEHNINGER TA, TURNER SC et al: Human natural killer cells: a unique innate immunoregulatory role for the CD 56 bright subset. Blood (2001) 97:3146–3151.
   PubMed Web of Science ®Google Scholar
• MATERA L: Minireview: endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci. (1996) 59:599–614.
   PubMed Web of Science ®Google Scholar
• FERRAG F, GOFFIN V, BUTEAU H, KELLY PA: Immune function of prolactin and signal transduction by PRUGH cytokine receptors: specificity, redundancy and lessons from chimaeras. Cytokin. Cell Mol Ther. (1997) 3:197–213.
   PubMedGoogle Scholar
• WOODY MA, WELNIAK LA, RICHARDS S etal.: Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation. Neuroimmurromodulation (1999) 6:69–80.
   Google Scholar
• LETTERIO JJ, ROBERTS AB: Regulationof immune responses by TGF-I3. Amu. Rev Immurrol (1998) 16:137–161.
   PubMed Web of Science ®Google Scholar
• PARIHAR R, NADELLA P, JENSEN R, DIERKSHEIDE J, SHAPIRO C, CARSON W: A Phase I trial of Herceptin and Interleukin 12 in patients with HER-2/ neu overexpressing malignancies. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 1031.
   Google Scholar
• •IL-12 as a mfisb adjuvant induces CR in 1/5 metastatic breast cancer patients.
   Google Scholar
• STEINBRINK K, JONULEIT H, MULLER G et al: Interleukin -10 treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+Tcells resulting in failure to lyse tumor cells. Blood (1999) 93: 1634-1642.
   Google Scholar
• MORSE MA, MOSCA PJ, HOBEIKA A et al.: Immunotherapy with F1t3-Ligand mobilized dendritic cells loaded with carcinoembryonic antigen peptide in patients with metastatic malignancies expressing CEA. 36th anNual Meeting of the American Socieo, of Oncology (ASCO), (2000). Abstract 1840.
   Google Scholar
• MENETRIER-CAUX C, THOMACHOT MC, ALBERTI L, MONTMAIN G, BLAY JY: IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res. (2001) 61:3096–3104.
   PubMed Web of Science ®Google Scholar
• NAKANISHI K, YOSHIMOTO T, TSUTSUI H, OKAMURA H: Interleukin - 18 is a unique cytokine that stimulates both Thl and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev (2001) 12:53–72.
   PubMed Web of Science ®Google Scholar
• DE MAGALHAES-SILVERMAN M, DONNENBERG A, LEMBERSKY B et al.: Post-transplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. j Immunother. (2000) 23:154–160.
   PubMed Web of Science ®Google Scholar
• WOOD GW, DANSEY RD, KLEIN JL et al.: Combined modality high dose chemotherapy followed by adoptive immunotherapy to eliminate minimal residual disease in metastatic breast cancer. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 390.
   Google Scholar
• BRENNER M, ROSSIG C, SILI U: Virus and tumor specific cytotoxic T cell therapy. Hematology 2000. American Sot:leo, of Hematology Education Program Book. San Francisco (2000):356–360.
   Google Scholar
• GRIBBEN JG: Antibody - mediated purging. In: Hematopoetic Cell Transplantation. Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science (1999):207–216.
   Google Scholar
• COLVIN OM: Pharmacological purging of bone marrow. In: Hematopoetic Cell Transplantation. Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science, Boston (1999):217–224.
   Google Scholar
• JOHNSEN HE, HUTCHINGS M, TAANING E et al: Selective loss of progenitor subsets following CD34+ cell enrichment by magnetic field, magnetic beads or chromatography separation. Bone Marrow Transplant. (1999) 24:1329–1336.
   PubMed Web of Science ®Google Scholar
• MOHR M, HILGENFELD E, FIETZ T et al.: Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high dose therapy. Clin Cancer Res. (1999) 5:1035–1040.
   PubMed Web of Science ®Google Scholar
• HUANG Y, YANG J, WANG XB, BECKER FF, GASCOYNE PR: The removal of human breast cancer cells from hematopoietic CD34+ stem cells by dielectrophoretric field-flow-fraction. Hematother. Stem Cell Res. (1999) 8:481–490.
   PubMedGoogle Scholar
• HIRAI M, KELSEY LS, VAILLANCOURT M, MANEVAL DC, WATANABE T, TALMADGE JE: Purging of human breast cancer cells from stem cell products with an adenovirus containing p53. Cancer Gene Ther. (2000) 7:197–206.
   PubMed Web of Science ®Google Scholar
• WU A, MAZUMDER A, MARTUZA RL et al: Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. (2001) 61:3009–3015.
   PubMed Web of Science ®Google Scholar
• SPYRIDONIDIS A, BERNHARDT W, BEHRINGER D et al: Proliferation and survival of mammary carcinoma cells are influenced by culture conditions used for ex vivo expansion of CD 34+ blood progenitor cells. Blood (1999) 93:746–755.
   PubMed Web of Science ®Google Scholar
• BRASSEUR N. MENARD I, FORGET A et al.: Eradication of multiple myeloma and breast cancer cells by TH9402 mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants. Photochem. Photobiol (2000) 72:780–787.
   Google Scholar
• WILLIAMS SE RIZZO D, WU J, ANTMAN K, HOROWITZ M: Syngeneic stem cell transplantation in metastatic breast cancer. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 2018.
   Google Scholar
• •IBMTR report: relapse rates in auto-PBSCT are not increased compared to syngeneic PBSCT.
   Google Scholar
• WHITE C, WEAVER R, GRILLO - LOPEZ A: Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev Med. (2000) 52:125–145.
   Web of Science ®Google Scholar
• •Review on requirements of mAb to succeed in tumour cell destruction
   Google Scholar
• COBLEIGH MA, VOGEL CL, TRIPATHY D etal.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 - overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. I OM. Oncol (1999) 17:2639.
   Google Scholar
• RHA SY, TOLCHER AW, STEPHENSON J etal.: A Phase I study of Brevarex, a murine monoclonal antibody directed at the MUC1 antigen in patients with advanced solid tumors. 36th Annual Meeting of the American Socieo, of Oncology (ASCO) (2000). Abstract 1868.
   Google Scholar
• SLAMON DJ, LEYLAND JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl. j Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• MANGEL J, BUCKSTEIN R, IMRIE K et al.: Combined autologous stem cell transplantation and immunotherapy with rituxan in patients with newly diagnosed mantle cell lymphoma. 37th Annual Meeting of the American Socieo, of Oncology (ASCO) (2001). Abstract 2670.
   Google Scholar
• ILLIDGE TM, BROCK S: Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Curr. Pharm. Des. (2000) 6:1399–1418.
   PubMed Web of Science ®Google Scholar
• RICHMAN CM, DE NARDO SJ, O'DONNELL et al.: Dosimetry based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin-A. Clin Cancer Res. (1999) 5\(Suppl. 10):3243s–3248s.
   Google Scholar
• VOSE JM, BIERMAN PJ, LYNCH JC et al.: Radioimmunotherapy with Bexxar combined with high dose chemotherapy followed by autologous hematopoietic stem cell transplantation for refractory non-Hodgkin's lymphoma: synergistic results with no added toxicity. 37th Annual Meeting of the American Socieo, of Oncology (ASCO) (2001). Abstract 19.
   Google Scholar
• MURRAY JL: Monoclonal antibody treatment of solid tumors: a coming of age.
   Google Scholar
• Expert Op/n. Biol. Ther. (2001) 1(6) Semin. Oncol. (2000) 27(6 Suppl. 11):64–70 Discussion 92–100.
   Google Scholar
• BROWN RE, BERNATH AM, LEWIS GO: HER-2/neu protein-receptor-positive breast carcinoma: an immunologic perspective. Ann. OM. Lab. Sci. (2000) 30:249–258.
   PubMed Web of Science ®Google Scholar
• RICHARDS SM, GARMAN RD, KEYES L, KAVANAGH B, MC PHERSON JM: Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas. Cell Immunol (1998) 184:85–91.
   PubMed Web of Science ®Google Scholar
• REPP R, VAN OJIK H, VALERIUS TH et al.: Phase I trial of bispecific antibody MDX-H210 ( Fcy RI X HER-2/neu) up to high doses in combination with G-CSF in patients with metastatic breast cancer. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 1865.
   Google Scholar
• REILLY RT, MACHIELS JP, EMENS LA et al: The collaboration of both humoral and cellular HER-2/neu targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res. (2001) 61:880–883.
   PubMed Web of Science ®Google Scholar
• SCANLAN MJ: Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. (2001) 3:95–98.
   PubMed Web of Science ®Google Scholar
• •Review on problems like tumour antigen loss interfering with development of successful vaccines for breast cancer.
   Google Scholar
• BOCCIA M, BRONTE V, COLOMBO MP etal.: Antitumor Vaccination: where we stand. Haematologica (2000) 85:1172–1206.
   Google Scholar
• JIANG XP, YANG DC, ELLIOTT RL, HEAD JF: Vaccination with a mixed vaccine of autologenous and allogeneic breast cancer cells and tumor associated antigens CA15-3,CEA and CA125 results in immune and clinical responses in breast cancer patients. Cancer Biother. Radiopharm. (2000) 15:495–505.
   PubMed Web of Science ®Google Scholar
• BHATTACHARAYA-CHATTERJEE M, CHATTERJEE SK, FOON KA: The anti-idiotype vaccines for immunotherapy. Curr. Opin. Mol Ther. (2001) 3:63–69.
   PubMed Web of Science ®Google Scholar
• KNUTSON KL, SCHIFFMAN K, DISIS ML: Immunization with a HER2/neu helper peptide vaccine generates HER-2/ neu CD8 T cell immunity in cancer patients. j OM. Invest. (2001) 107:477–484.
   PubMed Web of Science ®Google Scholar
• DOEHN C, JOCHAM D: Technology evaluation: TG-1031, transgene SA. Curr. Opin. Mol Ther. (2000) 2:106–111.
   PubMed Web of Science ®Google Scholar
• SCHOLL SM, BALLOUL JM, LE GOC G etal.: Recombinant vaccinia virus encoding human MUC1 and IL-2 as immunotherapy in patients with breast cancer. Immunother. (2000) 23:570–580.
   Google Scholar
• MORSE MA, DENG Y, COLEMAN D et al.: A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1) pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. OM. Cancer Res. (1999) 5:1331–1338.
   Web of Science ®Google Scholar
• BRAUN SE, CHEN K, FOSTER RG et al: The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. j Immunol (2000) 164:4025–4031.
   PubMed Web of Science ®Google Scholar
• BRAUN SE, CHEN K, BLAZAR P et al.: F1t3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony stimulating factor and a potential mechanism, of action. Hum. Gene Ther. (1999) 10:2141.
   PubMed Web of Science ®Google Scholar
• DE ZOETEN EF, CARR-BRENDEL V, MARKOVIC D, TAYLOR-PAPADIMITROU J, COHEN EP: Immunity to breast cancer in mice immunized with semi-allogeneic fibroblasts transfected with DNA from breast cancer cells. j Immunol (1999) 162:6934–6941.
   PubMed Web of Science ®Google Scholar
• COHEN EP: DNA-based vaccines for the treatment of cancer - an experimental model. Trends Mol Med. (2001) 7:175–179.
   PubMed Web of Science ®Google Scholar
• MORSE MA: Technology evaluation: Theratope, Biomira Inc. Curr. Opin. Mol Ther. (2000) 2:453–458.
   PubMed Web of Science ®Google Scholar
• KIM SH, CAREW JF, KOOBY DA et at: Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single cycle herpes virus in squamous cell cancer. Cancer Gene Ther. (2000) 7:1279–1285.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO, WIEMANN M, NAYAK SK et al.: Interferon gamma or granulocyte macrophage colony stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short term cell line cultures: a randomized phase II trial of the cancer biotherapy research group. 37th Annual Meeting of the American Socieo, of Oncology (ASCO) (2001). Abstract 1092.
   Google Scholar
• SONG K, CHANG Y, PRUDHOMME GJ: IL-12 plasmid- enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice. Gene Ther. (2000) 7:1527–1535.
   PubMed Web of Science ®Google Scholar
• CAMPBELL I, MAGLIOCCO A, MOYANA T, ZHENG C, XIANG J: Adenovirus - mediated p16INK4 gene transfer significantly suppresses human breast cancer growth. Cancer Gene Ther. (2000) 7:1270–1278.
   PubMed Web of Science ®Google Scholar
• MAJUMDAR AS, ZOLOTOREV A, SAMUEL S et al.: Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. (2000) 7:1086–1099.
   PubMed Web of Science ®Google Scholar
• HOOD AF, VOGELSANG GB, BLACK LP et al.: Acute graft versus host disease: development following autologous and syngeneic bone marrow transplantation. Arch. Dermatol. (1987) 123:745–750.
   PubMed Web of Science ®Google Scholar
• SICA S, CHIUSOLO P, SALUTARI P et al.: Autologous graft versus host disease after CD34+ purified autologous peripheral blood progenitor cell transplantation. Hematother. Stem Cell Res. (2000) 9:375–379.
   PubMedGoogle Scholar
• HESS AD, JONES RJ: Autologous graft versus host disease. In: Hematopoietic Cell Transplantation' (Edition 2). Thomas ED, Blume KG, Forman SJ (Eds.), Blackwell Science, Boston (1999):342–348.
   Google Scholar
• KENNEDY MJ, VOGELSANG GB, JONES RJ et al.: Phase I trial of interferon gamma to potentiate cyclosporine induced graft versus host disease in women undergoing autologous bone marrow transplantation for breast cancer. j Chit. Oncol (1994) 12:249–257.
   PubMed Web of Science ®Google Scholar
• VOGELSANG GB, BITTON RJ, PIANTADOSI S et al: Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma - interferon trial. Bone Marrow Transplant. (1999) 24:637–640.
   PubMed Web of Science ®Google Scholar
• BARON F, GOHOT A, SALMON JP et al.: Clinical course and predictive factors for cyclosporine-induced autologous graft versus host disease after autologous haematopoietic stem cell transplantation. Br j Haematol (2000) 111:745–753.
   PubMed Web of Science ®Google Scholar
• MARIN GH, PORTO A, PRATES V et al.: Graft versus host disease in autologous stem cell transplantation. j Exp. Chit. Cancer Res. (1999) 18:201–208.
   PubMed Web of Science ®Google Scholar
• HIESTAND PC, MEKLER P, NORDMANN R, GRIEDER A, PERMMONGKOL CH: Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc. Nati Acad. Sci. USA (1986) 83:2599–2603.
   PubMed Web of Science ®Google Scholar
• •Competitive inhibition of prolactin and cyclosporine at therapeutic levels.
   Google Scholar
• RECCHIA F, DEFILIPPIS S, ROSSELLI M eta].: Phase II study of interleukin-2 and 13 -cisretinoic acid as maintenance therapy in advanced cancer. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 1053.
   Google Scholar
• KIANG DT, PAN W, KOLLANDER R, YANG J, KENNEDY BJ: Modulation of HER2 oncogene by ALL-trans-retinoic acid via AP-2 transcription factor in human breast cancer cells. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 1683.
   Google Scholar
• GIACCONE G, PUNT C, ANDO Y etal.: KRN7000, an NKT cell enhancer, in patients with solid tumours - a Phase I study of EORTC BTDG. 36th Annual Meeting of the American Society of Oncology (ASCO) (2000). Abstract 1871.
   Google Scholar
• VREDENBURGH J, LONG G BLACKWELL K et al.: Thalidomide modulates vascular endothelial growth factor (VEGF) levels post autologous peripheral blood progenitor cell transplantation in patients with metastatic breast cancer. 36th Annual Meeting of the American Sado, of Oncology (ASCO) (2000). Abstract 599.
   Google Scholar
• BAIDAS SM, WINER EP, FLEMING GF et al.: Phase II evaluation of thalidomide in patients with metastatic breast cancer. Oncol. (2000) 18:2710–2717.
   Google Scholar
• GABRILOVICH DI, CHEN HL, GIRGIS KR etat Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. (1996) 2:1096–1103.
   PubMed Web of Science ®Google Scholar
• NATHAN PD, WALKER D, BRIDLE H et al.: A phase II study investigating the use of thalidomide in conjunction with interferon-a in patients with metastatic renal cell carcinoma. 37th Annual Meeting of the American Society of Oncology (ASCO) (2001). Abstract 1058.
   Google Scholar
• HATTOREI K, HIRANO T, OSHIMI K, YAGITA H, OKUMURA K: A metalloproteinase inhibitor prevents acute graft versus host disease while preserving the graft versus leukaemia effect of allogeneic bone marrow transplantation. Leuk. Lymphoma (2000) 38:553–561.
   PubMed Web of Science ®Google Scholar
• RINGDEN, PABOPIN M, GORIN NC et al.: Is there a graft versus leukaemia effect in the absence of graft versus host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br. Haematol. (2000) 111:1130–1137.
   Google Scholar
• SOIFFER RJ, MURRAY C, GONIN R et al.: Effect of low dose interleukin-2 on disease relapse after T-cell depleted allogeneic bone marrow transplantation. Blood (1994) 84:964–971.
   PubMed Web of Science ®Google Scholar
• ROBINSON N, SANDERS JE, BENYUNES MC et al.: Phase I trial of IL-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood (1996) 87:1249–1254.
   PubMed Web of Science ®Google Scholar
• DAZZI F, GOLDMAN J: Donor lymhocyte infusions. Curr. Opin. Hematol. (1999) 6:394–399.
   PubMedGoogle Scholar
• •Review on adoptive immunotherapy after allo-SCT.
   Google Scholar
• MACKINNON S: Donor leukocyte infusions. Baillieres Clin. Haematol. (1997) 10:357–367.
   PubMedGoogle Scholar
• SLAVIN S, NAPARSTEK E, NAGLER A et al.: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood (1996) 87:2195–2204.
   PubMed Web of Science ®Google Scholar
• •New approaches to DLI by adding cytokines.
   Google Scholar
• LAWS HJ, NURNBERGER W, KORHOLZ D et al.: Successful treatment of relapsed CML after cord blood transplantation with donor leukocyte infusion IL-2 and IFN-alpha. Bone Marrow Transplant: (2000) 25(2):219–222.
   PubMed Web of Science ®Google Scholar
• LEDA M, LADON D, PIECZONKA A et al.: Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk. Res. (2001) 25:353–357.
   PubMed Web of Science ®Google Scholar
• FLOWERS ME, LEISENRING W, BEACH K et al.: Granulocyte colony stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with conor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biol. Blood Marrow Transplant: (2000) 6(3A):321–326.
   Google Scholar
• WALLER EK, BOYER M: New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T-cells. Bone Marrow Transplant. (2000) 25\(Suppl. 2):520–524.
   Google Scholar
• MARTINO R, MARTIN-HENAO G, SURADA A et al.: Allogeneic peripheral blood stem cell transplantation with CD 34+ cell selection and delayed T cell add back in adults. Result of a single center pilot study. Haematologica (2000) 85:1165–1171.
   PubMed Web of Science ®Google Scholar
• CORNELISSEN JJ, LOWENBERG B: Developments in T-cell depletion of allogeneic stem cell grafts. Cun: Opin. Hematol. (2000) 7:348–353.
   PubMed Web of Science ®Google Scholar
• •New approaches like delayed add back and selective depletion are reviewed.
   Google Scholar
• FOWLER DH, GRESS RE: Th2 and Tc2 cells in the regulation of GVHD, GVL and graft rejection: considerations for the allogeneic transplantation therapy of leukaemia and lymphoma. Leuk. Lymphoma (2000) 38:221–234.
   PubMed Web of Science ®Google Scholar
• BLAZAR BR, KWON BS, PANOSKALTSIS-MORTARI A, KWAK KB, PESCHON JJ, TAYLOR PA: Ligation of 4-1BB (CDw137) regulates graft versus host disease graft versus leukaemia and graft rejection in allogeneic bone marrow transplant recipients. j Immurrol. (2001) 166:3174–3183.
   Web of Science ®Google Scholar
• GOKER H, HAZNEDAROGLU IC, CHAO NJ: Acute graft versus host disease: pathobiology and management. Exp. Hematol. (2001) 29:259–277.
   PubMed Web of Science ®Google Scholar
• EIBL B, SCHWAIGHOFER H, NACHBAUR D: Evidence for a graft versus tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood(1996) 88:1501–1508.
   PubMed Web of Science ®Google Scholar
• BAY JO, CHOUFI B, POMEL C et al.: Potential allogeneic graft versustumor effect in a patients with ovarian cancer. Bone Marrow Transplant. (2000) 25:681–682.
   PubMed Web of Science ®Google Scholar
• CHILDS R, CHERNOFF A, CONTENTIN N etal.: Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation. N Engl. Med. (2000) 343:750–758.
   Google Scholar
• LIMA M, BONAMINO M, VASCONCELOS Z et al: Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of Expert Opin. Biol. Ther. (2001) 1(6)
   Google Scholar